AHA Scientific Sessions - American Heart Association Scientific Sessions

Discover how triple combination therapy for hypertension enhances cardiovascular health, as endorsed by the AHA and supported by pharmacists.

Olezarsen effectively lowers triglycerides and enhances cardiovascular health, especially when combined with fibrates, benefiting pharmacists and patients alike.

New triglyceride-lowering therapy Olezarsen significantly reduces severe hypertriglyceridemia and acute pancreatitis risk, offering hope for patients.

An expert highlights the need for early detection of aortic stenosis symptoms in elderly patients, urging pharmacists and clinicians to monitor subtle changes.

Biykem Bozkurt, MD, PhD, FACC highlights the need for reliable activity monitoring in heart failure care, addressing challenges of digital wearables in clinical practice.

New research reveals GLP-1 receptor agonists like semaglutide offer heart failure benefits beyond weight loss, emphasizing pharmacists' crucial role in patient care.

Pharmacists play a crucial role in holistic healthcare, enhancing patient care through education and collaboration with allied health professionals.

Pharmacists enhance LDL cholesterol management with tailored solutions like enlicitide, improving patient adherence and outcomes in cardiovascular care.

Discover how objective activity monitoring with accelerometers transforms cardiovascular risk assessment and treatment evaluation, enhancing patient care for pharmacists.

Expert highlights the benefits of early combination therapy in hypertension management, emphasizing improved blood pressure control and reduced side effects.

Expert reveals ongoing disparities in heart valve disease care, stressing the need for improved diagnosis and treatment equity for vulnerable populations.

Boehringer Ingelheim showcases its commitment to cardio-kidney-metabolic research, highlighting innovative therapies and advancements at AHA 2025.

Discover how emerging therapies in cardio-kidney-metabolic health reshape disease management at AHA 2025, highlighting interconnected health pathways.

Integrating a pharmacist into multidisciplinary settings allowed for more thorough LDL-C lowering in unique settings.

A new wrist-worn accelerometer device effectively monitors activity levels in heart failure patients, revealing critical insights into cardiovascular health.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.

Combining GLP-1 RA therapy with healthy lifestyle habits significantly reduces cardiovascular risk in type 2 diabetes patients, enhancing heart health outcomes.

Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.

Long-term melatonin use for insomnia raises heart failure risks, highlighting the need for careful evaluation of sleep aids and underlying health issues.